Novel Fused Heterocycles as 5‑HT2A Receptor Agonists for Treating Neurological Diseases, Namely, Depression, Anxiety, Substance Abuse, and Headaches

  • ACS Med Chem Lett. 2025 Aug 13;16(9):1715-1716. doi: 10.1021/acsmedchemlett.5c00477.
Ram W Sabnis  1
Affiliations
  • 1. Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Atlanta, Georgia 30309, United States.
PMID: 40959255 DOI: 10.1021/acsmedchemlett.5c00477
Abstract

Provided herein are novel fused heterocycles as 5-HT2A receptor agonists, pharmaceutical compositions, use of such compounds in treating neurological diseases, namely depression, anxiety, substance abuse and headaches, and processes for preparing such compounds.

Products